Wexford Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Wexford Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-230	Closed	-$104K	–	186
2020 Q2	$104K	Buy	+230	New	+$101K	0.03%	119

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Wexford Capital's BIO Position: Q3 2020 in Review

Wexford Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2020, closing a stake of 230 shares — an estimated $104K sold.

Wexford Capital first reported a position in BIO in Q2 2020 and held it in 1 quarter. The position peaked at $104K in Q2 2020. 479 funds tracked by Wall St. Rank hold BIO as of Q3 2020.

Wexford Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2020 after selling out during the quarter.
Wexford Capital sold 230 Bio-Rad Laboratories Class A shares in Q3 2020, an estimated $104K.
Wexford Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 1 quarter.
Wexford Capital's Bio-Rad Laboratories Class A position peaked at $104K in Q2 2020.
479 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2020.

Based on Wexford Capital's 13F filing for Q3 2020, filed 16 Nov 2020.